{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T21:12:05Z","timestamp":1794863525173,"version":"4.9.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T00:00:00Z","timestamp":1765497600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"vor","delay-in-days":38,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Canada\u2019s Drug Agency's Post-Market Drug Evaluation Program"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"DOI":"10.1186\/s10194-025-02167-0","type":"journal-article","created":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T04:47:26Z","timestamp":1765514846000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Persistence, switching, and healthcare use after initiating calcitonin gene-related peptide inhibitors: a real-world assessment"],"prefix":"10.1186","volume":"27","author":[{"given":"Cristiano S.","family":"Moura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason R.","family":"Randall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Klarenbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassan","family":"Behlouli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huong","family":"Luu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farnaz","family":"Amoozegar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Luc","family":"Kabor\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sasha","family":"Bernatsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,12]]},"reference":[{"key":"2167_CR1","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1016\/S0140-6736(20)32160-7","volume":"397","author":"M Ashina","year":"2021","unstructured":"Ashina M, Katsarava Z, Do TP, Buse DC, Pozo-Rosich P, \u00d6zge A, Krymchantowski AV, Lebedeva ER, Ravishankar K, Yu S, Sacco S, Ashina S, Younis S, Steiner TJ, Lipton RB (2021) Migraine: epidemiology and systems of care. Lancet 397:1485\u20131495. https:\/\/doi.org\/10.1016\/S0140-6736(20)32160-7","journal-title":"Lancet"},{"key":"2167_CR2","doi-asserted-by":"publisher","first-page":"e293","DOI":"10.1097\/j.pain.0000000000002275","volume":"163","author":"S Safiri","year":"2022","unstructured":"Safiri S, Pourfathi H, Eagan A, Mansournia MA, Khodayari MT, Sullman MJM, Kaufman J, Collins G, Dai H, Bragazzi NL, Kolahi A-A (2022) Global, regional, and national burden of migraine in 204 countries and territories, 1990 to 2019. Pain 163:e293\u2013e309. https:\/\/doi.org\/10.1097\/j.pain.0000000000002275","journal-title":"Pain"},{"key":"2167_CR3","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1111\/head.13281","volume":"58","author":"R Burch","year":"2018","unstructured":"Burch R, Rizzoli P, Loder E (2018) The prevalence and impact of migraine and severe headache in the United States: figures and trends from government health studies. Headache 58:496\u2013505. https:\/\/doi.org\/10.1111\/head.13281","journal-title":"Headache"},{"key":"2167_CR4","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1111\/head.14709","volume":"64","author":"F Cohen","year":"2024","unstructured":"Cohen F, Brooks CV, Sun D, Buse DC, Reed ML, Fanning KM, Lipton RB (2024) Prevalence and burden of migraine in the United States: a systematic review. Headache 64:516\u2013532. https:\/\/doi.org\/10.1111\/head.14709","journal-title":"Headache"},{"key":"2167_CR5","doi-asserted-by":"publisher","first-page":"300060522112638","DOI":"10.1177\/03000605221126380","volume":"50","author":"EB Graves","year":"2022","unstructured":"Graves EB, Gerber BR, Berrigan PS, Shaw E, Cowling TM, Ladouceur M-P, Bougie JK (2022) Epidemiology and treatment utilization for Canadian patients with migraine: a literature review. J Int Med Res 50:3000605221126380. https:\/\/doi.org\/10.1177\/03000605221126380","journal-title":"J Int Med Res"},{"key":"2167_CR6","first-page":"10","volume":"25","author":"PL Ramage-Morin","year":"2014","unstructured":"Ramage-Morin PL, Gilmour H (2014) Prevalence of migraine in the Canadian household population. Health Rep 25:10\u201316","journal-title":"Health Rep"},{"key":"2167_CR7","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1111\/head.13275","volume":"58","author":"M Bonafede","year":"2018","unstructured":"Bonafede M, Sapra S, Shah N, Tepper S, Cappell K, Desai P (2018) Direct and indirect healthcare resource utilization and costs among migraine patients in the united States. Headache 58:700\u2013714. https:\/\/doi.org\/10.1111\/head.13275","journal-title":"Headache"},{"key":"2167_CR8","unstructured":"Migraine | National Institute of Neurological Disorders and Stroke https:\/\/www.ninds.nih.gov\/health-information\/disorders\/migraine. Accessed 5 Nov 2024"},{"key":"2167_CR9","doi-asserted-by":"publisher","first-page":"3654","DOI":"10.1007\/s00415-023-11706-1","volume":"270","author":"F Puledda","year":"2023","unstructured":"Puledda F, Silva EM, Suwanlaong K, Goadsby PJ (2023) Migraine: from pathophysiology to treatment. J Neurol 270:3654\u20133666. https:\/\/doi.org\/10.1007\/s00415-023-11706-1","journal-title":"J Neurol"},{"key":"2167_CR10","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s40263-015-0253-z","volume":"29","author":"S Wrobel Goldberg","year":"2015","unstructured":"Wrobel Goldberg S, Silberstein SD (2015) Targeting CGRP: a new era for migraine treatment. CNS Drugs 29:443\u2013452. https:\/\/doi.org\/10.1007\/s40263-015-0253-z","journal-title":"CNS Drugs"},{"key":"2167_CR11","doi-asserted-by":"publisher","first-page":"3527","DOI":"10.3390\/ijms20143527","volume":"20","author":"I-H Huang","year":"2019","unstructured":"Huang I-H, Wu P-C, Lin E-Y, Chen C-Y, Kang Y-N (2019) Effects of anti-calcitonin gene-related peptide for migraines: a systematic review with meta-analysis of randomized clinical trials. Int J Mol Sci 20:3527. https:\/\/doi.org\/10.3390\/ijms20143527","journal-title":"Int J Mol Sci"},{"key":"2167_CR12","doi-asserted-by":"publisher","first-page":"363","DOI":"10.3389\/fphar.2019.00363","volume":"10","author":"D Scuteri","year":"2019","unstructured":"Scuteri D, Adornetto A, Rombol\u00e0 L, Naturale MD, Morrone LA, Bagetta G, Tonin P, Corasaniti MT (2019) New trends in migraine pharmacology: targeting calcitonin gene-related peptide (CGRP) with monoclonal antibodies. Front Pharmacol 10:363. https:\/\/doi.org\/10.3389\/fphar.2019.00363","journal-title":"Front Pharmacol"},{"key":"2167_CR13","doi-asserted-by":"publisher","unstructured":"Charles AC, Digre KB, Goadsby PJ, Robbins MS, Hershey A, American Headache Society (2024) calcitonin gene-related peptide-targeting therapies are a first-line option for the prevention of migraine: an American Headache Society position statement update. Headache 64:333\u2013341. https:\/\/doi.org\/10.1111\/head.14692","DOI":"10.1111\/head.14692"},{"key":"2167_CR14","doi-asserted-by":"publisher","unstructured":"Medrea I, Cooper P, Langman M, Sandoe CH, Amoozegar F, Hussain WM, Bradi AC, Dawe J, Guay M, Perreault F, Reid S, Todd C, Skidmore B, Christie SN (2024) Updated Canadian headache society migraine prevention guideline with systematic review and Meta-analysis. Can J Neurol Sci J Can Sci Neurol 1\u201323. https:\/\/doi.org\/10.1017\/cjn.2024.285","DOI":"10.1017\/cjn.2024.285"},{"key":"2167_CR15","unstructured":"Canadian Agency for Drugs and Technologies in Health (CADTH) (2020) CADTH Canadian drug expert committee recommendation: erenumab (Aimovig). Canadian Agency for Drugs and Technologies in Health (CADTH)"},{"key":"2167_CR16","unstructured":"Canadian Agency for Drugs and Technologies in Health (CADTH) (2021) CADTH reimbursement recommendation: emgality (Galcanezumab). Canadian Agency for Drugs and Technologies in Health (CADTH)"},{"key":"2167_CR17","doi-asserted-by":"publisher","first-page":"e117","DOI":"10.37765\/ajmc.2023.89352","volume":"29","author":"L Musial","year":"2023","unstructured":"Musial L, Kheloussi S (2023) Prior authorization requirements for calcitonin gene-related peptide antagonists. Am J Manag Care 29:e117\u2013e123. https:\/\/doi.org\/10.37765\/ajmc.2023.89352","journal-title":"Am J Manag Care"},{"key":"2167_CR18","doi-asserted-by":"publisher","first-page":"821","DOI":"10.2147\/PPA.S346660","volume":"16","author":"OJ Varnado","year":"2022","unstructured":"Varnado OJ, Manjelievskaia J, Ye W, Perry A, Schuh K, Wenzel R (2022) Treatment patterns for calcitonin gene-related peptide monoclonal antibodies including galcanezumab versus conventional preventive treatments for migraine: a retrospective US claims study. Patient Prefer Adherence 16:821\u2013839. https:\/\/doi.org\/10.2147\/PPA.S346660","journal-title":"Patient Prefer Adherence"},{"key":"2167_CR19","unstructured":"Canadian Agency for Drugs and Technologies in Health (CADTH) (2023) CADTH health technology assessment report: HC0081. Canadian Agency for Drugs and Technologies in Health (CADTH)"},{"key":"2167_CR20","unstructured":"MarketScan Research Databases for life sciences researchers https:\/\/www.merative.com\/content\/dam\/merative\/documents\/brief\/marketscan-research-databases-for-life-sciences-researchers.pdf. Accessed 20 Nov 2024"},{"key":"2167_CR21","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1080\/03007995.2024.2410930","volume":"40","author":"J Ailani","year":"2024","unstructured":"Ailani J, Lewis M, Dai F, Jenkins A, Cirillo J, Hygge Blakeman K, Abraham L, Brown J (2024) Evaluation of rimegepant utilization patterns and patient characteristics among new users: a united States administrative claims-based study. Curr Med Res Opin 40:1913\u20131920. https:\/\/doi.org\/10.1080\/03007995.2024.2410930","journal-title":"Curr Med Res Opin"},{"key":"2167_CR22","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","volume":"43","author":"H Quan","year":"2005","unstructured":"Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi J-C, Saunders LD, Beck CA, Feasby TE, Ghali WA (2005) Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 43:1130\u20131139. https:\/\/doi.org\/10.1097\/01.mlr.0000182534.19832.83","journal-title":"Med Care"},{"key":"2167_CR23","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s10072-020-04643-8","volume":"41","author":"G Allais","year":"2020","unstructured":"Allais G, Chiarle G, Sinigaglia S, Airola G, Schiapparelli P, Benedetto C (2020) Gender-related differences in migraine. Neurol Sci 41:429\u2013436. https:\/\/doi.org\/10.1007\/s10072-020-04643-8","journal-title":"Neurol Sci"},{"key":"2167_CR24","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s10194-022-01476-y","volume":"23","author":"JL Nguyen","year":"2022","unstructured":"Nguyen JL, Munshi K, Peasah SK, Swart ECS, Kohli M, Henderson R, Good CB (2022) Trends in utilization and costs of migraine medications, 2017\u20132020. J Headache Pain 23:111. https:\/\/doi.org\/10.1186\/s10194-022-01476-y","journal-title":"J Headache Pain"},{"key":"2167_CR25","doi-asserted-by":"publisher","first-page":"211","DOI":"10.3949\/ccjm.87a.19048","volume":"87","author":"J Bucklan","year":"2020","unstructured":"Bucklan J, Ahmed Z (2020) CGRP antagonists for decreasing migraine frequency: new options, long overdue. Cleve Clin J Med 87:211\u2013218. https:\/\/doi.org\/10.3949\/ccjm.87a.19048","journal-title":"Cleve Clin J Med"},{"key":"2167_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-020-01177-4","author":"DC Buse","year":"2020","unstructured":"Buse DC, Gandhi SK, Cohen JM, Ramirez-Campos V, Cloud B, Yang R, Cowan RP (2020) Improvements across a range of patient-reported domains with fremanezumab treatment: results from a patient survey study. J Headache Pain. https:\/\/doi.org\/10.1186\/s10194-020-01177-4","journal-title":"J Headache Pain"},{"key":"2167_CR27","doi-asserted-by":"publisher","first-page":"300","DOI":"10.3988\/jcn.2023.0311","volume":"20","author":"MS Youn","year":"2024","unstructured":"Youn MS, Kim N, Lee MJ, Kim M (2024) Treatment outcome after switching from galcanezumab to fremanezumab in patients with migraine. J Clin Neurol Seoul Korea 20:300\u2013305. https:\/\/doi.org\/10.3988\/jcn.2023.0311","journal-title":"J Clin Neurol Seoul Korea"},{"key":"2167_CR28","doi-asserted-by":"publisher","first-page":"274","DOI":"10.3390\/neurolint16010019","volume":"16","author":"R Suliman","year":"2024","unstructured":"Suliman R, Santos V, Al Qaisi I, Aldaher B, Al Fardan A, Al Barrawy H, Bader Y, Supena JL, Alejandro K, Alsaadi T (2024) Effectiveness of switching CGRP monoclonal antibodies in non-responder patients in the UAE: a retrospective study. Neurol Int 16:274\u2013288. https:\/\/doi.org\/10.3390\/neurolint16010019","journal-title":"Neurol Int"},{"key":"2167_CR29","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1177\/03331024211048765","volume":"42","author":"LH Overeem","year":"2022","unstructured":"Overeem LH, Peikert A, Hofacker MD, Kamm K, Ruscheweyh R, Gendolla A, Raffaelli B, Reuter U, Neeb L (2022) Effect of antibody switch in non-responders to a CGRP receptor antibody treatment in migraine: a multi-center retrospective cohort study. Cephalalgia 42:291\u2013301. https:\/\/doi.org\/10.1177\/03331024211048765","journal-title":"Cephalalgia"},{"key":"2167_CR30","doi-asserted-by":"publisher","first-page":"529","DOI":"10.3390\/toxins14080529","volume":"14","author":"D Scuteri","year":"2022","unstructured":"Scuteri D, Tonin P, Nicotera P, Vulnera M, Altieri GC, Tarsitano A, Bagetta G, Corasaniti MT (2022) Pooled analysis of real-world evidence supports anti-CGRP mAbs and OnabotulinumtoxinA combined trial in chronic migraine. Toxins 14:529. https:\/\/doi.org\/10.3390\/toxins14080529","journal-title":"Toxins"},{"key":"2167_CR31","doi-asserted-by":"publisher","first-page":"69","DOI":"10.2147\/PPA.S437396","volume":"18","author":"OJ Varnado","year":"2024","unstructured":"Varnado OJ, Brady BL, Zagar AJ, Robles YP, Hoyt M (2024) Comparison of treatment patterns in patients with migraine initiating calcitonin gene-related peptide monoclonal antibodies: a retrospective real-world US study. Patient Prefer Adherence 18:69\u201388. https:\/\/doi.org\/10.2147\/PPA.S437396","journal-title":"Patient Prefer Adherence"},{"key":"2167_CR32","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s10194-021-01238-2","volume":"22","author":"SJ Tepper","year":"2021","unstructured":"Tepper SJ, Fang J, Vo P, Shen Y, Zhou L, Abdrabboh A, Glassberg M, Ferraris M (2021) Impact of erenumab on acute medication usage and health care resource utilization among migraine patients: a US claims database study. J Headache Pain 22:27. https:\/\/doi.org\/10.1186\/s10194-021-01238-2","journal-title":"J Headache Pain"},{"key":"2167_CR33","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1007\/s40122-021-00319-z","volume":"10","author":"D Chandler","year":"2021","unstructured":"Chandler D, Szekely C, Aggarwal S, Cyprien L, Bensink M (2021) Migraine characteristics, comorbidities, healthcare resource utilization, and associated costs of early users of erenumab in the USA: a retrospective cohort study using administrative claims data. Pain Ther 10:1551\u20131566. https:\/\/doi.org\/10.1007\/s40122-021-00319-z","journal-title":"Pain Ther"},{"key":"2167_CR34","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1007\/s40122-024-00644-z","volume":"13","author":"R Urman","year":"2024","unstructured":"Urman R, Princic N, Vuvu F, Patel LB, Oh S, Chandler D, Hindiyeh N, Bensink ME (2024) Changes in use of migraine medications, healthcare resource utilization, and associated direct costs over 12 months following initiation of erenumab: a US retrospective real-world analysis. Pain Ther 13:1299\u20131313. https:\/\/doi.org\/10.1007\/s40122-024-00644-z","journal-title":"Pain Ther"},{"key":"2167_CR35","doi-asserted-by":"publisher","first-page":"818","DOI":"10.18553\/jmcp.2022.28.8.818","volume":"28","author":"OJ Varnado","year":"2022","unstructured":"Varnado OJ, Manjelievskaia J, Ye W, Perry A, Schuh K, Wenzel R (2022) Health care resource utilization and costs associated with treatment among patients initiating calcitonin gene-related peptide inhibitors vs other preventive migraine treatments in the united States. J Manag Care Spec Pharm 28:818\u2013829. https:\/\/doi.org\/10.18553\/jmcp.2022.28.8.818","journal-title":"J Manag Care Spec Pharm"},{"key":"2167_CR36","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1111\/head.14244","volume":"62","author":"J Ailani","year":"2022","unstructured":"Ailani J, Blumenfeld AM (2022) Combination CGRP monoclonal antibody and OnabotulinumtoxinA treatment for preventive treatment in chronic migraine. Headache 62:106\u2013108. https:\/\/doi.org\/10.1111\/head.14244","journal-title":"Headache"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-025-02167-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-025-02167-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-025-02167-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T17:28:05Z","timestamp":1768843685000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s10194-025-02167-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,12]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2167"],"URL":"https:\/\/doi.org\/10.1186\/s10194-025-02167-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7013231\/v1","asserted-by":"object"}]},"ISSN":["1129-2377"],"issn-type":[{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,12]]},"assertion":[{"value":"30 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Research Ethics Office of the Faculty of Medicine, McGill University (IRB Study Number A04-M47-12B). Informed consent is not applicable because the study used de-identified claims data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and\/or publication of this manuscript: JRR, HL, and SK are members of the Alberta Real World Evidence Consortium (ARWEC) and the Alberta Drug and Therapeutic Evaluation Consortium (ADTEC); these entities (comprised of individuals from the University of Alberta, University of Calgary, and Institutes of Health Economics) conduct research including investigator-initiated industry-funded studies (ARWEC) and government-funded studies (ADTEC). FA reports receiving research support from Eli Lilly, Allergan\/Abbvie, Biohaven, Novartis, and Teva; consulting fees from Eli Lilly, Novartis, Teva, Lundbeck, ICEBM, and Pfizer; and speaker honoraria from Eli Lilly, Novartis, Teva, Allergan\/Abbvie, ICEBM, and Aralez. All other authors report no conflict.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"19"}}